Literature DB >> 35253097

SARS-CoV-2 variants, immune escape, and countermeasures.

Yi Zhang1, Haocheng Zhang1, Wenhong Zhang2,3.   

Abstract

Coronavirus disease 2019 (COVID-19) has become a global pandemic disease. SARS-CoV-2 variants have aroused great concern and are expected to continue spreading. Although many countries have promoted roll-out vaccination, the immune barrier has not yet been fully established, indicating that populations remain susceptible to infection. In this review, we summarize the literature on variants of concern and focus on the changes in their transmissibility, pathogenicity, and resistance to the immunity constructed by current vaccines. Furthermore, we analyzed relationships between variants and breakthrough infections, as well as the paradigm of new variants in countries with high vaccination rates. Terminating transmission, continuing to strengthen variant surveillance, and combining nonpharmaceutical intervention measures and vaccines are necessary to control these variants.
© 2022. Higher Education Press.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; breakthrough; immune escape; prevention; vaccine

Mesh:

Substances:

Year:  2022        PMID: 35253097      PMCID: PMC8898658          DOI: 10.1007/s11684-021-0906-x

Source DB:  PubMed          Journal:  Front Med        ISSN: 2095-0217            Impact factor:   9.927


  72 in total

1.  COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence.

Authors:  Felipe Gomes Naveca; Valdinete Nascimento; Victor Costa de Souza; André de Lima Corado; Fernanda Nascimento; George Silva; Ágatha Costa; Débora Duarte; Karina Pessoa; Matilde Mejía; Maria Júlia Brandão; Michele Jesus; Luciana Gonçalves; Cristiano Fernandes da Costa; Vanderson Sampaio; Daniel Barros; Marineide Silva; Tirza Mattos; Gemilson Pontes; Ligia Abdalla; João Hugo Santos; Ighor Arantes; Filipe Zimmer Dezordi; Marilda Mendonça Siqueira; Gabriel Luz Wallau; Paola Cristina Resende; Edson Delatorre; Tiago Gräf; Gonzalo Bello
Journal:  Nat Med       Date:  2021-05-25       Impact factor: 53.440

2.  Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals.

Authors:  Oren Milman; Idan Yelin; Noga Aharony; Rachel Katz; Esma Herzel; Amir Ben-Tov; Jacob Kuint; Sivan Gazit; Gabriel Chodick; Tal Patalon; Roy Kishony
Journal:  Nat Med       Date:  2021-06-10       Impact factor: 53.440

3.  A pneumonia outbreak associated with a new coronavirus of probable bat origin.

Authors:  Peng Zhou; Xing-Lou Yang; Xian-Guang Wang; Ben Hu; Lei Zhang; Wei Zhang; Hao-Rui Si; Yan Zhu; Bei Li; Chao-Lin Huang; Hui-Dong Chen; Jing Chen; Yun Luo; Hua Guo; Ren-Di Jiang; Mei-Qin Liu; Ying Chen; Xu-Rui Shen; Xi Wang; Xiao-Shuang Zheng; Kai Zhao; Quan-Jiao Chen; Fei Deng; Lin-Lin Liu; Bing Yan; Fa-Xian Zhan; Yan-Yi Wang; Geng-Fu Xiao; Zheng-Li Shi
Journal:  Nature       Date:  2020-02-03       Impact factor: 69.504

4.  Site-specific glycan analysis of the SARS-CoV-2 spike.

Authors:  Yasunori Watanabe; Joel D Allen; Daniel Wrapp; Jason S McLellan; Max Crispin
Journal:  Science       Date:  2020-05-04       Impact factor: 47.728

5.  Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.

Authors:  Piyada Supasa; Daming Zhou; Wanwisa Dejnirattisai; Chang Liu; Alexander J Mentzer; Helen M Ginn; Yuguang Zhao; Helen M E Duyvesteyn; Rungtiwa Nutalai; Aekkachai Tuekprakhon; Beibei Wang; Guido C Paesen; Jose Slon-Campos; César López-Camacho; Bassam Hallis; Naomi Coombes; Kevin R Bewley; Sue Charlton; Thomas S Walter; Eleanor Barnes; Susanna J Dunachie; Donal Skelly; Sheila F Lumley; Natalie Baker; Imam Shaik; Holly E Humphries; Kerry Godwin; Nick Gent; Alex Sienkiewicz; Christina Dold; Robert Levin; Tao Dong; Andrew J Pollard; Julian C Knight; Paul Klenerman; Derrick Crook; Teresa Lambe; Elizabeth Clutterbuck; Sagida Bibi; Amy Flaxman; Mustapha Bittaye; Sandra Belij-Rammerstorfer; Sarah Gilbert; David R Hall; Mark A Williams; Neil G Paterson; William James; Miles W Carroll; Elizabeth E Fry; Juthathip Mongkolsapaya; Jingshan Ren; David I Stuart; Gavin R Screaton
Journal:  Cell       Date:  2021-02-18       Impact factor: 41.582

6.  Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016.

Authors:  Tyler N Starr; Allison J Greaney; Adam S Dingens; Jesse D Bloom
Journal:  Cell Rep Med       Date:  2021-04-05

7.  Identification of a novel SARS-CoV-2 P.1 sub-lineage in Brazil provides new insights about the mechanisms of emergence of variants of concern.

Authors:  Tiago Gräf; Gonzalo Bello; Taina Moreira Martins Venas; Elisa Cavalcante Pereira; Anna Carolina Dias Paixão; Luciana Reis Appolinario; Renata Serrano Lopes; Ana Carolina Da Fonseca Mendonça; Alice Sampaio Barreto da Rocha; Fernando Couto Motta; Tatiana Schäffer Gregianini; Richard Steiner Salvato; Sandra Bianchini Fernandes; Darcita Buerger Rovaris; Andrea Cony Cavalcanti; Anderson Brandão Leite; Irina Riediger; Maria do Carmo Debur; André Felipe Leal Bernardes; Rodrigo Ribeiro-Rodrigues; Beatriz Grinsztejn; Valdinete Alves do Nascimento; Victor Costa de Souza; Luciana Gonçalves; Cristiano Fernandes da Costa; Tirza Mattos; Filipe Zimmer Dezordi; Gabriel Luz Wallau; Felipe Gomes Naveca; Edson Delatorre; Marilda Mendonça Siqueira; Paola Cristina Resende
Journal:  Virus Evol       Date:  2021-12-15

8.  The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies.

Authors:  Richard Copin; Alina Baum; Elzbieta Wloga; Kristen E Pascal; Stephanie Giordano; Benjamin O Fulton; Anbo Zhou; Nicole Negron; Kathryn Lanza; Newton Chan; Angel Coppola; Joyce Chiu; Min Ni; Yi Wei; Gurinder S Atwal; Annabel Romero Hernandez; Kei Saotome; Yi Zhou; Matthew C Franklin; Andrea T Hooper; Shane McCarthy; Sara Hamon; Jennifer D Hamilton; Hilary M Staples; Kendra Alfson; Ricardo Carrion; Shazia Ali; Thomas Norton; Selin Somersan-Karakaya; Sumathi Sivapalasingam; Gary A Herman; David M Weinreich; Leah Lipsich; Neil Stahl; Andrew J Murphy; George D Yancopoulos; Christos A Kyratsous
Journal:  Cell       Date:  2021-06-05       Impact factor: 41.582

9.  AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC.

Authors:  Emma C Wall; Mary Wu; Ruth Harvey; Gavin Kelly; Scott Warchal; Chelsea Sawyer; Rodney Daniels; Lorin Adams; Philip Hobson; Emine Hatipoglu; Yenting Ngai; Saira Hussain; Karen Ambrose; Steve Hindmarsh; Rupert Beale; Andrew Riddell; Steve Gamblin; Michael Howell; George Kassiotis; Vincenzo Libri; Bryan Williams; Charles Swanton; Sonia Gandhi; David Lv Bauer
Journal:  Lancet       Date:  2021-06-28       Impact factor: 79.321

10.  SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.

Authors:  Aziz Sheikh; Jim McMenamin; Bob Taylor; Chris Robertson
Journal:  Lancet       Date:  2021-06-14       Impact factor: 79.321

View more
  4 in total

1.  The impact of SARS-CoV-2 on respiratory syndromic and sentinel surveillance in Israel, 2020: a new perspective on established systems.

Authors:  Aharona Glatman-Freedman; Lea Gur-Arie; Hanna Sefty; Zalman Kaufman; Michal Bromberg; Rita Dichtiar; Alina Rosenberg; Rakefet Pando; Ital Nemet; Limor Kliker; Ella Mendelson; Lital Keinan-Boker; Neta S Zuckerman; Michal Mandelboim
Journal:  Euro Surveill       Date:  2022-04

Review 2.  Recent Progress on Rapid Lateral Flow Assay-Based Early Diagnosis of COVID-19.

Authors:  Ying Zhang; Yujuan Chai; Zulu Hu; Zhourui Xu; Meirong Li; Xin Chen; Chengbin Yang; Jia Liu
Journal:  Front Bioeng Biotechnol       Date:  2022-05-03

3.  The mutation features and geographical distributions of the surface glycoprotein (S gene) in SARS-CoV-2 strains: A comparative analysis of the early and current strains.

Authors:  Rang Liu; Xinran Lin; Bing Chen; Zhenhui Hou; Qiuju Zhang; Shouren Lin; Lan Geng; Zhongyi Sun; Canhui Cao; Yu Shi; Xi Xia
Journal:  J Med Virol       Date:  2022-08-06       Impact factor: 20.693

Review 4.  Updates on Coronavirus Disease 2019 in Children in Japan.

Authors:  Yuta Aizawa; Sayaka Takanashi; Chikara Ogimi
Journal:  Pediatr Infect Dis J       Date:  2022-07-18       Impact factor: 3.806

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.